We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Neuronascent Licenses its Patented Animal Cells to Lifeline Cell Technology
News

Neuronascent Licenses its Patented Animal Cells to Lifeline Cell Technology

Neuronascent Licenses its Patented Animal Cells to Lifeline Cell Technology
News

Neuronascent Licenses its Patented Animal Cells to Lifeline Cell Technology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Neuronascent Licenses its Patented Animal Cells to Lifeline Cell Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Neuronascent, Inc. has announced the license of animal cells to Lifeline Cell Technology, LLC, a wholly owned subsidiary of International Stem Cell Corporation.

The worldwide exclusive license covers the marketing, sale and distribution of adult Arctic ground squirrel (AGS) neural stem cells for research use and provides Neuronascent with license fees and royalty income.

The Arctic ground squirrel is the only known mammal capable of lowering its body temperature to below freezing during hibernation. Scientists believe that this tolerance makes AGS cells a unique clinically-relevant model for the study of cerebral ischemia. Dr. Kelly Drew, a collaborator from the University of Alaska-Fairbanks and the Institute for Arctic Biology, summed it up by saying, "Neuronascent has captured tolerance to cerebral ischemia in a neural stem cell line derived from Arctic ground squirrels. This unique extremophile can now be explored by scientists throughout the world."

"Neuronascent is excited to partner with Lifeline Cell Technology in the commercialization of this unique and useful product," said Judith Kelleher-Andersson, Ph.D., President and Chief Scientific Officer of Neuronascent. Dr. Kelleher-Andersson went on to say, "We hope this agreement provides for the distribution of a new research tool for identifying novel therapeutic targets and for animal transplantation research."

Advertisement